First US clinical cases successfully conducted with EndoDrill GI
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of the world’s first market-cleared motorized endoscopic core biopsy instrument, announces that the first US clinical procedures with EndoDrill®...
BiBB receives approval of two patents in Europe for EndoDrill
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”) today announces that the European Patent Office (EPO) has finally approved two patent applications for EndoDrill®. The patents provide broad protection...
BiBB reports positive results from clinical pilot study with EndoDrill URO
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”) today reports that the first clinical study with EndoDrill® URO for muscle-invasive bladder cancer has been scientifically published in European Urology...
BIBB informs about the status of the CE marking process according to MDR
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), which develops and manufactures a new type of electric-driven endoscopic biopsy instrument, EndoDrill®, hereby provides a status update on the CE...
BIBB receives market clearance for EndoDrill GI in the US
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), which develops and manufactures a new type of electric-driven endoscopic biopsy instrument, EndoDrill®, announces that the Company has now received a...
BiBB receives another Intention to Grant notice for EndoDrill in Europe
Today, the cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”) announces that the Company has received an additional Intention to Grant from the European Patent Office (“EPO”). The announcement means...
BiBB receives an Intention to Grant for electric-driven EndoDrill in Europe
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”) announces that the Company has received an Intention to Grant from the European Patent Office (EPO). This means that EPO intends...